Current and future prospects for a vaccine for nontypeable Haemophilus influenzae

Current Infectious Disease Reports

Volumn 11, Issue 3, 2009, Pages 177-182

  Murphy, Timothy F ^a  

^a VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; HAEMOPHILUS ADHESIN PROTEIN; HAEMOPHILUS INFLUENZAE ADHESIN; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS A VACCINE; HIGH MOLECULAR WEIGHT PROTEIN 1; HIGH MOLECULAR WEIGHT PROTEIN 2; LIPOOLIGOSACCHARIDE; LIPOPROTEIN D; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN 26; OUTER MEMBRANE PROTEIN P4; P2 PORIN; P5 FIMBRIN; P6 PROTEIN; PHOSPHORYLCHOLINE; PNEUMOCOCCUS VACCINE; PROTEIN D PNEUMOCOCCAL CONJUGATE VACCINE; PROTEIN D15; PROTEIN E; PROTEIN HTRA; TYPE IV PILUS PROTEIN; UNCLASSIFIED DRUG;

BACTERIAL STRAIN; BACTERIUM CULTURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; ENDOLYMPH; FEASIBILITY STUDY; GENETIC HETEROGENEITY; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOGENICITY; IMMUNOPHARMACOLOGY; MORBIDITY; NONHUMAN; OTITIS MEDIA; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE;

EID: 65649086031     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0027-1     Document Type: Review

References (50)

1. Murphy TF, Faden H, Bakaletz LO, et al.: Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J 2009, 28:43-48.
2. Brook I, Foote PA, Hausfeld JN: Frequency of recovery of pathogens causing acute maxillary sinusitis in adults before and after introduction of vaccination of children with the 7-valent pneumococcal vaccine. J Med Microbiol 2006, 55:943-946.
3. Brook I, Gober AE: Frequency of recovery of pathogens from the nasopharynx of children with acute maxillary sinusitis before and after the introduction of vaccination with the 7-valent pneumococcal vaccine. Int J Pediatr Otorhinolaryngol 2007, 71:575-579.
4. Sethi S, Murphy TF: Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008, 359:2355-2365.
5. Hausdorff WP, Dagan R: Serotypes and pathogens in paediatric pneumonia. Vaccine 2008, 26(Suppl 2):B19-B23.
6. American Academy of Pediatrics: Diagnosis and management of acute otitis media. Pediatrics 2004, 113:1451-1465.
7. Schilder AG, Lok W, Rovers MM: International perspectives on management of acute otitis media: A qualitative review. Int J Pediatr Otorhinolaryngol 2004, 68:29-36.
8. Alsarraf R, Gates GA: The real cost of otitis media. Acta Paediatr 1999, 88:487-488.
9. Brouwer CN, Rovers MM, Maille AR, et al.: The impact of recurrent acute otitis media on the quality of life of children and their caregivers. Clin Otolaryngol 2005, 30:258-265.
10. Lee J, Witsell DL, Dolor RJ, et al.: Quality of life of patients with otitis media and caregivers: A multicenter study. Laryngoscope 2006, 116:1798-1804.
11. Niemela M, Uhari M, Mottonen M, Pokka T: Costs arising from otitis media. Acta Paediatr 1999, 88:553-556.
12. O'Neill P: Acute otitis media. BMJ 1999, 319:833-835.
13. Faden H: The microbiologic and immunologic basis for recurrent otitis media in children. Eur J Pediatr 2001, 160:407-413.
14. Ruohola A, Meurman O, Nikkari S, et al.: Microbiology of acute otitis media in children with tympanostomy tubes: Prevalences of bacteria and viruses. Clin Infect Dis 2006, 43: 1417-1422.
15. Arguedas A, Dagan R, Leibovitz E, et al.: A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection. Pediatr Infect Dis J 2006, 25:211-218.
16. Kilpi T, Herva E, Kaijalainen T, et al.: Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life. Pediatr Infect Dis J 2001, 20:654-662.
17. Gehanno P, Panajotopoulos A, Barry B, et al.: Microbiology of otitis media in the Paris, France, area from 1987 to 1997. Pediatr Infect Dis J 2001, 20:570-573.
18. Casey JR, Pichichero ME: Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 2004, 23:824-828.
19. Block SL, Hedrick J, Harrison CJ, et al.: Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004, 23:829-833.
20. Eskola J, Kilpi T, Palmu A, et al.: Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344:403-409.
21. Revai K, McCormick DP, Patel J, et al.: Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics 2006, 117:1823-1829.
22. Fletcher MA, Fritzell B: Brief review of the clinical effectiveness of PREVENAR against otitis media. Vaccine 2007, 25:2507-2512.
23. Leibovitz E, JacobA MR, Dagan R: Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr Infect Dis J 2004, 23:1142-1152.
24. Faden H, Brodsky L, Waz MJ, et al.: Nasopharyngeal flora in the first three years of life in normal and otitis-prone children. Ann Otol Rhinol Laryngol 1991, 100:612-615.
25. Ambrosino DM, Umetsu DT, Siber GR, et al.: Selective defect in the antibody response to Haemophilus influenzae type b in children with recurrent infections and normal serum IgG subclass levels. J Allergy Clin Immunol 1988, 81:1175-1179.
26. Chonmaitree T, Revai K, Grady JJ, et al.: Viral upper respiratory tract infection and otitis media complication in young children. Clin Infect Dis 2008, 46:815-823.
27. Makela PH, Leinonen M, Pukander J, Karma P: A study of the pneumococcal vaccine in prevention of clinically acute attacks of recurrent otitis media. Rev Infect Dis 1981, 3:S124-S130.
28. Sloyer JL Jr, Ploussard JH, Howie VM: Efficacy of pneumococcal polysaccharide vaccine in preventing acute otitis media in infants in Huntsville, Alabama. Rev Infect Dis 1981, 3:S119-S123.
29. Shurin PA, Rehmus JM, Johnson CE, et al.: Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children. J Pediatr 1993, 123:801-810.
30. Faden H, Bernstein J, Brodsky L, et al.: Otitis media in children. I. The systemic immune response to nontypable Haemophilus influenzae. J Infect Dis 1989, 160:999-1004.
31. Prymula R, Peeters P, Chrobok V, et al.: Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: A randomised double-blind efficacy study. Lancet 2006, 367:740-748.
32. Novotny LA, Jurcisek JA, Godfroid F, et al.: Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae. Vaccine 2006, 24:4804-4811.
33. Forsgren A, Riesbeck K, Janson A: Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis 2008, 46:726-731.
34. Toropainen M, Raitolehto A, Henckaerts I, et al.: Pneumococcal Haemophilus influenzae protein D conjugate vaccine induces antibodies that inhibit glycerophosphodiester phosphodiesterase activity of protein D. Infect Immun 2008, 76:4546-4553.
35. Fan X, Goldfine H, Lysenko E, Weiser JN: The transfer of choline from the host to the bacterial cell surface requires glpQ in Haemophilus influenzae. Mol Microbiol 2001, 41:1029-1036.
36. Neary JM, Murphy TF: Antibodies directed at a conserved motif in loop 6 of outer membrane protein P2 of nontypeable Haemophilus influenzae recognize multiple strains in immunoassays. FEMS Immunol Med Microbiol 2006, 46:251-261.
37. Ostberg KO, Russell MW, Murphy TF: Mucosal immunization of mice with recombinant OMP P2 induces antibodies that bind to surface epitopes of multiple strains of nontypeable Haemophilus influenzae. Mucosal Immunol 2009, 2:63-73.
38. Hou Y, Gu XX: Development of peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccine candidates. J Immunol 2003, 170:4373-4379.
39. Wu T, Chen J, Murphy TF, et al.: Investigation of non-type-able Haemophilus influenzae outer membrane protein P6 as a new carrier for lipooligosaccharide conjugate vaccines. Vaccine 2005, 23:5177-5185.
40. Giebink GS, Kurono Y, Bakaletz LO, et al.: Recent advances in otitis media. 6. Vaccine. Ann Otol Rhinol Laryngol Suppl 2005, 194:86-103.
41. Murphy TF, Bakaletz LO, Kyd JM, et al.: Vaccines for otitis media: proposals for overcoming obstacles to progress. Vaccine 2005, 23:2696-2702.
42. Liu DF, Mason KW, Mastri M, et al.: The C-terminal fragment of the internal 110-kilodalton passenger domain of the Hap protein of nontypeable Haemophilus influenzae is a potential vaccine candidate. Infect Immun 2004, 72:6961-6968.
43. Winter LE, Barenkamp SJ: Antibodies specific for the high-molecular-weight adhesion proteins of nontypeable Haemophilus influenzae are opsonophagocytic for both homologous and heterologous strains. Clin Vaccine Immunol 2006, 13:1333-1342.
44. Kyd JM, Cripps AW, Novotny LA, Bakaletz LO: Efficacy of the 26-kilodalton outer membrane protein and two P5 fimbrin-derived immunogens to induce clearance of nontypeable Haemophilus influenzae from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx. Infect Immun 2003, 71:4691-4699.
45. Kyd JM, Cripps AW: Potential of a novel protein, OMP26, from nontypeable Haemophilus influenzae to enhance pulmonary clearance in a rat model. Infect Immun 1998, 66:2272-2278.
46. Abe Y, Murphy TF, Sethi S, et al.: Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 165:967-971.
47. Sabirov A, Kodama S, Sabirova N, et al.: Intranasal immunization with outer membrane protein P6 and cholera toxin induces specific sinus mucosal immunity and enhances sinus clearance of nontypeable Haemophilus influenzae. Vaccine 2004, 22:3112-3121.
48. Ronander E, Brant M, Janson H, et al.: Identification of a novel Haemophilus influenzae protein important for adhesion to epithelial cells. Microbes Infect 2008, 10:87-96.
49. Jurcisek JA, Bookwalter JE, Baker BD, et al.: The PilA protein of non-typeable Haemophilus influenzae plays a role in biofilm formation, adherence to epithelial cells and colonization of the mammalian upper respiratory tract. Mol Microbiol 2007, 65:1288-1299.
50. Bakaletz LO, Baker BD, Jurcisek JA, et al.: Demonstration of type IV pilus expression and a twitching phenotype by Haemophilus influenzae. Infect Immun 2005, 73:1635-1643.